Remove 2020 Remove Drugs Remove Immune Response
article thumbnail

Predicting Adverse Reactions to Monoclonal Antibody Drugs

addgene Blog

Monoclonal antibody drugs are popular therapeutics for a plethora of disease conditions, from cancer to autoimmune disorders. Antibodies administered as drugs are still immunogenic, meaning that they elicit an immune response from the body.

article thumbnail

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BMS Psoriasis Drug Shows Positive Phase 3 Results | 2020-11-04

The Pharma Data

Bristol Myers Squibb (BMS) has reported positive results from a late-stage trial of its investigational drug, BMS-986165 (deucravacitinib), for treating moderate-to-severe plaque psoriasis. Deucravacitinib works by inhibiting the tyrosine kinase 2 (TYK2) enzyme, which is linked to an immune response that causes skin inflammation.

article thumbnail

Aleta’s Novel T Cell Engagers

SugarCone Biotech

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. Consequently, these drugs have limited ability to keep patients disease-free and limited impact on patient survival. Proc Natl Acad Sci U S A 115: E2068-E2076.

article thumbnail

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

The Pharma Data

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. Source link.

article thumbnail

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock – Oct 28, 2020

The Pharma Data

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. SAN DIEGO , Oct. Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00

article thumbnail

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

The Pharma Data

Food and Drug Administration in the coming days with additional submissions to other regulatory agencies worldwide to follow. Each serum was tested simultaneously for its neutralizing titer against recombinant SARS-CoV-2 (with USA-WA-1/2020 genetic backbone) bearing the wild-type SARS-CoV-2 spike protein and theOmicron spike.